Please use this identifier to cite or link to this item: https://doi.org/10.3892/ijo-00000669
Title: Liposomal M-V-05: Formulation development and activity testing of a novel dihydrofolate reductase inhibitor for breast cancer therapy
Authors: Tan, B.J. 
Quek, K.S.
Wong, M.-Y.
Chui, W.K. 
Chiu, G.N.C. 
Keywords: Dihydrofolate receptor
Drug combination
Liposomes
Metastatic breast cancer
Synergism
Issue Date: Jul-2010
Citation: Tan, B.J., Quek, K.S., Wong, M.-Y., Chui, W.K., Chiu, G.N.C. (2010-07). Liposomal M-V-05: Formulation development and activity testing of a novel dihydrofolate reductase inhibitor for breast cancer therapy. International Journal of Oncology 37 (1) : 211-218. ScholarBank@NUS Repository. https://doi.org/10.3892/ijo-00000669
Abstract: In the management of metastatic breast cancer, fewer recognized therapeutic standards are available as compared to the early stages of the disease. Thus, it is pertinent to search for new, effective therapy to improve survival, tolerability and quality of life of patients. In this study, a liposomal formulation was developed for a novel dihydrofolate reductase (DHFR) inhibitor, M-V-05. Drug encapsulation into liposomes was achieved by the citrate-based, pH gradient loading technique, with a final drug-to-lipid weight ratio of 0.1:1. The liposome formulation exhibited a sustained release profile of the encapsulated drug that followed first order release kinetics. Liposomal M-V-05 was found to be more effective than the standard DHFR inhibitor, methotrexate, and its activity was comparable to liposomal doxorubicin, with IC50 values of 37 and 59 μM achieved in MDA-MB-231 and JIMT-1 cells, respectively. Similar cytotoxicity was observed in primary patient samples of invasive ductal carcinoma of the breast. The combination of liposomal MV-05 and liposomal doxorubicin in fixed molar ratio of 3:1 was additive in cytotoxicity, allowing the concentrations of liposomal doxorubicin and liposomal M-V-05 to be reduced by 62 and 46%, respectively. Taken together, liposomal M-V-05 represents a promising agent and offers a potential new adjuvant therapy for breast cancer treatment.
Source Title: International Journal of Oncology
URI: http://scholarbank.nus.edu.sg/handle/10635/106113
ISSN: 10196439
DOI: 10.3892/ijo-00000669
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

4
checked on May 23, 2018

WEB OF SCIENCETM
Citations

5
checked on May 8, 2018

Page view(s)

36
checked on May 18, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.